Cytokine storm explained

Cytokine storm should not be confused with Cytokine release syndrome.

Cytokine storm
Synonyms:hypercytokinemia
Field:Immunology

A cytokine storm, also called hypercytokinemia, is a pathological reaction in humans and other animals in which the innate immune system causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines. Cytokines are a normal part of the body's immune response to infection, but their sudden release in large quantities may cause multisystem organ failure and death.[1]

Cytokine storms may be caused by infectious or non-infectious etiologies, especially viral respiratory infections such as H1N1 influenza, H5N1 influenza, SARS-CoV-1,[2] [3] SARS-CoV-2, Influenza B, and parainfluenza virus. Other causative agents include the Epstein-Barr virus, cytomegalovirus, group A streptococcus, and non-infectious conditions such as graft-versus-host disease.[4] The viruses can invade lung epithelial cells and alveolar macrophages to produce viral nucleic acid, which stimulates the infected cells to release cytokines and chemokines, activating macrophages, dendritic cells, and others.[5]

Cytokine storm syndrome is a diverse set of conditions that can result in a cytokine storm. Cytokine storm syndromes include familial hemophagocytic lymphohistiocytosis, Epstein-Barr virus–associated hemophagocytic lymphohistiocytosis, systemic or non-systemic juvenile idiopathic arthritis–associated macrophage activation syndrome, NLRC4 macrophage activation syndrome, cytokine release syndrome and sepsis.[6]

Cytokine storms versus cytokine release syndrome

The term "cytokine storm" is often loosely used interchangeably with cytokine release syndrome (CRS) but is more precisely a differentiable syndrome that may represent a severe episode of cytokine release syndrome or a component of another disease entity, such as macrophage activation syndrome. When occurring as a result of a therapy, CRS symptoms may be delayed until days or weeks after treatment. Immediate-onset (fulminant) CRS appears to be a cytokine storm.[7]

Research

Nicotinamide (a form of vitamin B3) is a potent inhibitor of proinflammatory cytokines.[8] [9] Low blood plasma levels of trigonelline (one of the metabolites of vitamin B3) have been suggested for the prognosis of SARS-CoV-2 death (which is thought to be due to the inflammatory phase and cytokine storm).[10] [11]

Magnesium decreases inflammatory cytokine production by modulation of the immune system.[12] [13]

History

The first reference to the term cytokine storm in the published medical literature appears to be by James Ferrara in 1993 during a discussion of graft vs. host disease, a condition in which the role of excessive and self-perpetuating cytokine release had already been under discussion for many years.[14] [15] [16] The term next appeared in a discussion of pancreatitis in 2002. In 2003, it was first used in reference to a reaction to an infection.

It is believed that cytokine storms were responsible for the disproportionate number of healthy young adult deaths during the 1918 influenza pandemic, which killed an estimated 50 million people worldwide. In this case, a healthy immune system may have been a liability rather than an asset.[17] Preliminary research results from Taiwan also indicated this as the probable reason for many deaths during the SARS epidemic in 2003.[18] Human deaths from the bird flu H5N1 usually involve cytokine storms as well.[19] Cytokine storm has also been implicated in hantavirus pulmonary syndrome.[20]

In 2006, a study at Northwick Park Hospital in England resulted in all 6 of the volunteers given the drug theralizumab becoming critically ill, with multiple organ failure, high fever, and a systemic inflammatory response.[21] Parexel, a company conducting trials for pharmaceutical companies claimed that theralizumab could cause a cytokine storm—the dangerous reaction the men experienced.[22]

Relationship to COVID-19

During the COVID-19 pandemic, some doctors have attributed many deaths to cytokine storms.[23] [24] A cytokine storm can cause the severe symptoms of acute respiratory distress syndrome (ARDS), which has a high mortality rate in COVID-19 patients.[25] SARS-CoV-2 activates the immune system resulting in a release of a large number of cytokines, including IL-6, which can increase vascular permeability and cause a migration of fluid and blood cells into the alveoli leading to such consequent symptoms as dyspnea and respiratory failure.[26] In an autopsy study from Karolinska Hospital, 29 pleural effusions of deceased COVID-19 patients were analyzed. Out of 184 protein markers, 20 markers were raised significantly in COVID-19 deceased patients. A group of markers showed over-stimulation of the immune system, including ADA, BTC, CA12, CAPG, CD40, CDCP1, CXCL9, ENTPD2, Flt3L, IL-6, IL-8, LRP1, OSM, PD-L1, PTN, STX8, and VEGFA; furthermore, DPP6 and EDIL3 indicated damage to arterial and cardiovascular organs. The higher mortality has been linked to the effects of ARDS aggravation and the tissue damage that can result in organ-failure and/or death.[27]

ARDS was shown to be the cause of mortality in 70% of COVID-19 deaths.[28] A cytokine plasma level analysis showed that in cases of severe SARS-CoV-2 infection, the levels of many interleukins and cytokines are highly elevated, indicating evidence of a cytokine storm. Additionally, postmortem examination of patients with COVID-19 has shown a large accumulation of inflammatory cells in lung tissues including macrophages and T-helper cells.[29]

Early recognition of a cytokine storm in COVID-19 patients is crucial to ensure the best outcome for recovery, allowing treatment with a variety of biological agents that target the cytokines to reduce their levels. Meta-analysis suggests clear patterns distinguishing patients with or without severe disease. Possible predictors of severe and fatal cases may include lymphopenia, thrombocytopenia and high levels of ferritin, D-dimer, aspartate aminotransferase, lactate dehydrogenase, C-reactive protein, neutrophils, procalcitonin and creatinine as well as interleukin-6 (IL-6). Ferritin and IL-6 are considered to be possible immunological biomarkers for severe and fatal cases of COVID-19. Ferritin and C-reactive protein may be possible screening tools for early diagnosis of systemic inflammatory response syndrome in cases of COVID-19.[30]

Due to the increased levels of cytokines and interferons in patients with severe COVID-19, both have been investigated as potential targets for SARS-CoV-2 therapy. An animal study found that mice producing an early strong interferon response to SARS-CoV-2 were likely to live, but in other cases the disease progressed to a highly morbid overactive immune system.[31] [32] The high mortality rate of COVID-19 in older populations has been attributed to the impact of age on interferon responses.

Short-term use of dexamethasone, a synthetic corticosteroid, has been demonstrated to reduce the severity of inflammation and lung damage induced by a cytokine storm by inhibiting the severe cytokine storm or the hyperinflammatory phase in patients with COVID-19.[33]

Clinical trials continue to identify causes of cytokine storms in COVID-19 cases.[34] [35] One such cause is the delayed Type I interferon response that leads to accumulation of pathogenic monocytes. High viremia is also associated with exacerbated Type I interferons response and worse prognosis.[36] Diabetes, hypertension, and cardiovascular disease are all risk factors of cytokine storms in COVID-19 patients.[37]

Notes and References

  1. 10.1007/s11739-020-02355-7. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: Could nicotine be a therapeutic option?. 2020. Farsalinos. Konstantinos. Barbouni. Anastasia. Niaura. Raymond. Internal and Emergency Medicine. 15. 5. 845–852. 32385628. 7210099. free.
  2. Wong. Jonathan P.. Viswanathan. Satya. Wang. Ming. Sun. Lun-Quan. Clark. Graeme C.. D'Elia. Riccardo V.. February 2017. Current and future developments in the treatment of virus-induced hypercytokinemia. Future Medicinal Chemistry. 9. 2. 169–178. 10.4155/fmc-2016-0181. 1756-8927. 7079716. 28128003.
  3. Liu . Qiang . Zhou . Yuan-hong . Yang . Zhan-qiu . The cytokine storm of severe influenza and development of immunomodulatory therapy . Cellular & Molecular Immunology . January 2016 . 13 . 1 . 3–10 . 10.1038/cmi.2015.74 . 26189369 . 4711683.
  4. Tisoncik. Jennifer R.. Korth. Marcus J.. Simmons. Cameron P.. Farrar. Jeremy. Martin. Thomas R.. Katze. Michael G.. 2012. Into the Eye of the Cytokine Storm. Microbiology and Molecular Biology Reviews . 76. 1. 16–32. 10.1128/MMBR.05015-11. 1092-2172. 3294426. 22390970.
  5. Song. Peipei. Li. Wei. Xie. Jianqin. Hou. Yanlong. You. Chongge. October 2020. Cytokine storm induced by SARS-CoV-2. Clinica Chimica Acta; International Journal of Clinical Chemistry. 509. 280–287. 10.1016/j.cca.2020.06.017. 0009-8981. 7283076. 32531256.
  6. Behrens. Edward M.. Koretzky. Gary A.. 2017. Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era. Arthritis & Rheumatology. en. 69. 6. 1135–1143. 10.1002/art.40071. 2326-5205. 28217930. free.
  7. Porter D, Frey N, Wood PA, Weng Y, Grupp SA . Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel . Journal of Hematology & Oncology . 11 . 1 . 35 . March 2018 . 29499750 . 5833070 . 10.1186/s13045-018-0571-y . free .
  8. Ungerstedt JS, Blömback M, Söderström T. 2003. Nicotinamide is a potent inhibitor of proinflammatory cytokines.. Clin Exp Immunol. 131. 1. 48–52. 10.1046/j.1365-2249.2003.02031.x. 1808598. 12519385.
  9. Yanez M, Jhanji M, Murphy K, Gower RM, Sajish M, Jabbarzadeh E. 2019. Nicotinamide Augments the Anti-Inflammatory Properties of Resveratrol through PARP1 Activation.. Sci Rep. 9. 1. 10219. 10.1038/s41598-019-46678-8. 6629694. 31308445. 2019NatSR...910219Y.
  10. Caterino, Marianna, Michele Costanzo, Roberta Fedele, Armando Cevenini, Monica Gelzo, Alessandro Di Minno, Immacolata Andolfo et al. "The serum metabolome of moderate and severe COVID-19 patients reflects possible liver alterations involving carbon and nitrogen metabolism." International journal of molecular sciences 22, no. 17 (2021): 9548.
  11. Blood Plasma Trigonelline Concentration and the Early Prognosis of Death in SARS-Cov-2 Patients. 10.5281/zenodo.5856445. 2021. Besharati. Mohammad Reza. Izadi. Mohammad. Alireza Talebpour.
  12. Sugimoto J, Romani AM, Valentin-Torres AM, Luciano AA, Ramirez Kitchen CM, Funderburg N. etal. 2012. Magnesium decreases inflammatory cytokine production: a novel innate immunomodulatory mechanism.. J Immunol. 188. 12. 6338–46. 10.4049/jimmunol.1101765. 3884513. 22611240.
  13. Nielsen FH. 2018. Magnesium deficiency and increased inflammation: current perspectives.. J Inflamm Res. 11. 25–34. 10.2147/JIR.S136742. 5783146. 29403302 . free .
  14. Clark . Ian A . The advent of the cytokine storm . Immunology & Cell Biology . June 2007 . 85 . 4 . 271–273 . 10.1038/sj.icb.7100062 . 17551531 . 40463322.
  15. Ferrara JL, Abhyankar S, Gilliland DG . Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1 . Transplantation Proceedings . 25 . 1 Pt 2 . 1216–7 . February 1993 . 8442093.
  16. Abhyankar. Sunil. Gilliland. D. Gary. Ferrara. James L.M.. 1993. . Transplantation. 56. 6. 1518–1522. 10.1097/00007890-199312000-00045. 8279027. 0041-1337. free.
  17. Osterholm MT . Preparing for the next pandemic . The New England Journal of Medicine . 352 . 18 . 1839–42 . May 2005 . 15872196 . 10.1056/NEJMp058068 . 10.1.1.608.6200 . 45893174 . Michael Osterholm.
  18. Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, Lei HY . An interferon-gamma-related cytokine storm in SARS patients . Journal of Medical Virology . 75 . 2 . 185–94 . February 2005 . 15602737 . 7166886 . 10.1002/jmv.20255.
  19. Haque A, Hober D, Kasper LH . Confronting potential influenza A (H5N1) pandemic with better vaccines . Emerging Infectious Diseases . 13 . 10 . 1512–8 . October 2007 . 18258000 . 2851514 . 10.3201/eid1310.061262.
  20. Mori M, Rothman AL, Kurane I, Montoya JM, Nolte KB, Norman JE, Waite DC, Koster FT, Ennis FA . 6 . High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome . The Journal of Infectious Diseases . 179 . 2 . 295–302 . February 1999 . 9878011 . 10.1086/314597 . free.
  21. High stakes, high risks . The Lancet. Oncology . 8 . 2 . 85 . February 2007 . 17267317 . 10.1016/S1470-2045(07)70004-9 . The Lancet Oncology.
  22. Web site: Mystery over drug trial debacle deepens . Coghlan A . 2006-08-14 . Health . New Scientist . 2009-04-29.
  23. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ . COVID-19: consider cytokine storm syndromes and immunosuppression . Lancet . 395 . 10229 . 1033–1034 . March 2020 . 32192578 . 10.1016/S0140-6736(20)30628-0 . 7270045 . free.
  24. Ruan Q, Yang K, Wang W, Jiang L, Song J . Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China . Intensive Care Medicine . March 2020 . 46 . 5 . 846–848 . 32125452 . 7080116 . 10.1007/s00134-020-05991-x.
  25. Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, Hirano T . How covid-19 induces cytokine storm with high mortality . Inflammation and Regeneration . October 2020 . 40 . 37 . 37 . 33014208 . 7527296 . 10.1186/s41232-020-00146-3 . free .
  26. Farsalinos. Konstantinos. Barbouni. Anastasia. Niaura. Raymond. 2020-05-09. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?. Internal and Emergency Medicine. 15. 5. 845–852. 10.1007/s11739-020-02355-7. 1828-0447. 7210099. 32385628.
  27. Ragad . Dina . The COVID-19 Cytokine Storm; What we know so far . Front. Immunol. . 16 June 2020 . 11 . 1446 . 10.3389/fimmu.2020.01446 . 32612617 . 7308649 . free .
  28. Hojyo. Shintaro. Uchida. Mona. Tanaka. Kumiko. Hasebe. Rie. Tanaka. Yuki. Murakami. Masaaki. Hirano. Toshio. 2020-10-01. How COVID-19 induces cytokine storm with high mortality. Inflammation and Regeneration. 40. 37. 10.1186/s41232-020-00146-3. 33014208. 1880-9693. 7527296 . free .
  29. Tang. Yujun. Liu. Jiajia. Zhang. Dingyi. Xu. Zhenghao. Ji. Jinjun. Wen. Chengping. 2020-07-10. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Frontiers in Immunology. 11. 1708. 10.3389/fimmu.2020.01708. 1664-3224. 7365923. 32754163. free.
  30. Melo . Ana Karla G. . Milby . Keilla M. . Caparroz . Ana Luiza M. A. . Pinto . Ana Carolina P. N. . Santos . Rodolfo R. P. . Rocha . Aline P. . Ferreira . Gilda A. . Souza . Viviane A. . Valadares . Lilian D. A. . Vieira . Rejane M. R. A. . Pileggi . Gecilmara S. . Trevisani . Virgínia F. M. . Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis . PLOS ONE . 29 June 2021 . 16 . 6 . e0253894 . 10.1371/journal.pone.0253894 . 34185801 . 8241122 . 2021PLoSO..1653894M . free .
  31. Channappanavar. Rudragouda. Perlman. Stanley. 2017. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars in Immunopathology. 39. 5. 529–539. 10.1007/s00281-017-0629-x. 28466096. 1863-2297. 7079893.
  32. News: Velasquez-Manoff. Moises. 2020-08-11. How Covid Sends Some Bodies to War With Themselves. en-US. The New York Times. 2020-12-28. 0362-4331.
  33. Sharun . Khan . Tiwari . Ruchi . Dhama . Jaideep . Dhama . Kuldeep . Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary evidence . International Journal of Surgery . October 2020 . 82 . 179–181 . 10.1016/j.ijsu.2020.08.038 . 32896649 . 7472975 .
  34. Hermine . Olivier . Mariette . Xavier . Tharaux . Pierre-Louis . Resche-Rigon . Matthieu . Porcher . Raphaël . Ravaud . Philippe . CORIMUNO-19 Collaborative Group . Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial . JAMA Internal Medicine . 20 October 2020 . 181 . 1 . 32–40 . 10.1001/jamainternmed.2020.6820 . 2168-6106 . 33080017 . 7577198.
  35. Gupta . Shruti . Wang . Wei . Hayek . Salim S. . Chan . Lili . Mathews . Kusum S. . Melamed . Michal L. . Brenner . Samantha K. . Leonberg-Yoo . Amanda . Schenck . Edward J. . Radbel . Jared . Reiser . Jochen . Bansal . Anip . Srivastava . Anand . Zhou . Yan . Finkel . Diana . Green . Adam . Mallappallil . Mary . Faugno . Anthony J. . Zhang . Jingjing . Velez . Juan Carlos Q. . Shaefi . Shahzad . Parikh . Chirag R. . Charytan . David M. . Athavale . Ambarish M. . Friedman . Allon N. . Redfern . Roberta E. . Short . Samuel A. P. . Correa . Simon . Pokharel . Kapil K. . Admon . Andrew J. . Donnelly . John P. . Gershengorn . Hayley B. . Douin . David J. . Semler . Matthew W. . Hernán . Miguel A. . Leaf . David E. . STOP-COVID Investigators . Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 . JAMA Internal Medicine . 20 October 2020 . 181 . 1 . 41–51 . 10.1001/jamainternmed.2020.6252 . 33080002 . 757720.
  36. Sa Ribero. Margarida. Jouvenet. Nolwenn. Dreux. Marlène. Nisole. Sébastien. 2020-07-29. Interplay between SARS-CoV-2 and the type I interferon response. PLOS Pathogens. 16. 7. e1008737. 10.1371/journal.ppat.1008737. 1553-7366. 7390284. 32726355 . free .
  37. Mangalmurti. Nilam. Hunter. Christopher A.. 14 July 2020. Cytokine Storms: Understanding COVID-19. Immunity. 53. 1. 19–25. 10.1016/j.immuni.2020.06.017. 32610079. 7321048.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Cytokine storm".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.